This article is more than 5 years old. Information may no longer be current.

Iridex receives two patents for laser delivery system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Patent Office has issued two patents for the TxCell scanning laser delivery system to cover key elements of Iridex’s MicroPulse technology and to improve the delivery of its subthreshold treatment for patients with glaucoma and retinal diseases, Iridex announced in a press release.

The two patents, No. 9,265,656 and No. 9,278,029, will cover automatic laser delivery with multi-spot pattern scanning for retinal photocoagulation that spares tissue and enables faster treatments.

“With TxCell-assisted scanning and delivery technologies, physicians using MicroPulse can more accurately visualize a treatment area and predictably and efficiently deliver the therapy. The issuance of these patents adds to Iridex’s extensive intellectual property portfolio and confirms Iridex’s leadership in the ophthalmology market with our TxCell and Cyclo G6 laser delivery systems,” Will Moore, president and CEO of Iridex, said in the release.